Press Releases

Global Minimal Residual Disease (MRD) Testing Market was estimated at USD 1.4 billion in 2023 and is poised to grow up to USD 3.4 billion by 2030, registering a CAGR of 14.7% during the forecast period ranging between 2025 and 2030.

Minimal residual disease (MRD) testing is a specific type of medical test which involves identifying and monitoring small amounts of cancer cells that may be left behind in a patient's body after undergoing a cancer treatment and may eventually relapse. This particular test can identify cancer cells of lymphoma, leukemia, multiple myeloma and even a few solid tumors. The growth of the global MRD testing market is primarily driven by the growing prevalence of hematologic malignancies. Development and use of innovative therapies, such as CAR T-cell therapy, needs precise assessment of treatment to determine its success which is facilitated by MRD testing, which promotes its demand and fuels market growth. The market faces significant challenges that impede its growth despite the positive growth prospects, like the high cost and limited accessibility of MRD tests in low-income regions. However, growth opportunities lie in the technological innovations that are lowering the cost of these tests and improving sensitivity and results. The market is expected to benefit significantly, with the improvement in healthcare infrastructurein emerging markets and government funding along with collaborative efforts.

Browse 63 market data Tables and 40 Figures spread through 198 Pages and in-depth TOC on Global Minimal Residual Disease (MRD) Testing Market By Test Type (Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Flow Cytometry and Others), By Application (Leukemia, Lymphoma, Myeloma and Others), By Therapy (Chemotherapy, Immunotherapy, Targeted Therapy and Stem Cell Therapy), By End User (Hospitals, Diagnostic Laboratories, Academic and Research Institutions and Others) and By Geography (North America and Asia) - Global Forecast from 2025 to 2030.

Global MRD Testing Market Segmentation and Key Players

By end use, PCR-based test section dominate the global minimal residual disease (MRD) testing market

The PCR-based test section currently dominates the market and is expected to do so in the forecast period due to the widespread use in detectingminimal residual disease in blood cancers.

"The North America is projected to register the fastest CAGR during the forecast period, i.e., 2025-2030 in the global minimal residual disease (MRD) testing market.”

North America currently dominates the global Minimal Residual Disease (MRD) Testing market, mainly due to its developed healthcare infrastructure, existence of large number of players in the region especially in US, higher government funding for cancer research, the growing focus of the region on precision medicine, and greater adoption of advanced diagnostic technologies.

Some of the key players in this market are Exact Sciences Corporation, GRAIL LLC, Guardant Health, mdxhealth, Bio-Techne, QIAGEN, Veracyte Inc., F.Hoffmann-La Roche Ltd, FOUNDATION MEDICINE INC, Natera Inc.

Recent Developments of Key Players

Bio-Techne Corporation has partnered with Discovery Life Sciences to add Lunaphore COMET (a best-in-class spatial biology platform) to Discovery's global suite of biospecimen products and specialty lab services that shall support customers with clinical research.

Qiagen has expanded its strategic partnership with Bio-Manguinhos (the leading provider of vaccines and diagnostics to the Brazilian Ministry of Health). With the expansion of this collaboration, Bio-Manguinhos shall launch an advanced PCR-based molecular screening platform to detect malaria alongside HIV, C virus (HBV and HCV), hepatitis B. 

The minimal residual disease (MRD) testing market report offers a comprehensive market segmentation analysis along with estimation for the forecast period 2025–2030.

Global Minimal Residual Disease (MRD) Testing Market coverage (By Value)

• Test Type Insight and Forecast 2025 - 2030
  • Polymerase Chain Reaction (PCR)
  • Next-Generation Sequencing (NGS)
  • Flow Cytometry and Others
• Application Insight and Forecast 2025 - 2030
  • Leukemia
  • Lymphoma
  • Myeloma 
  • Others
• Therapy Insight and Forecast 2025 - 2030
  • Chemotherapy
  • Immunotherapy
  • Targeted Therapy 
  • Stem Cell Therapy
• End User Insight and Forecast 2025 - 2030 
  • Hospitals
  • Diagnostic Laboratories
  • Academic and Research Institutions
  • Others

Geographical Segmentation

Global Minimal Residual Disease (MRD) Testing Market by Region

• North America
  • The U.S.
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific